Lower urinary tract symptoms and overactive bladder ... in men with overactive bladder and benign prostatic hyperplasia. With regard to efficacy, 80% of patients receiving tolterodine ER plus ...

The global Benign Prostatic Hyperplasia Surgical Treatment market, valued at US$11.92 billion in 2023, is forecasted to grow at a robust CAGR of 5.3%, reaching US$12.62 billion in 2024 and an ...

Men seeking urologic care, either through self-referral or clinician referral, often have knowledge gaps in BPH symptoms and treatment.

Men seeking urologic care, either through self-referral or clinician referral, often have knowledge gaps in BPH symptoms and ...

Benign Prostatic Hyperplasia (BPH) is diagnosed through a combination of medical history, physical examination, and specific tests. Here are the key diagnostic methods: Medical History: The doctor ...

Olympus Corporation of Asia Pacific (Olympus APAC) is launching its iTind device for treating benign prostatic hyperplasia ...

The global Benign Prostatic Hyperplasia Surgical Treatment market, valued at US$11.92 billion in 2023, is forecasted to grow at a robust CAGR ...

Dongkook Pharmaceutical announced on the 3rd that it has received approval for the item license of the world's first improved drug for benign ... lower urinary tract symptoms caused by benign ...

Opens in a new tab or window A hydroablation device for benign prostatic hyperplasia ... for prostate cancer with symptomatic lower urinary tract symptoms (LUTS) had an early spike in circulating ...